Table 1.
Characteristics According to Hydroxychloroquine Ever Use and Never Usea
| Variables | Hydroxychloroquine Ever Use (n=547) | Hydroxychloroquine Never Use (n=719) |
|---|---|---|
| Demographics | ||
| Age at RA diagnosis, y | 55±13 | 57±14 |
| Female (%) | 443 (80) | 510 (71) |
| White (%) | 526 (96) | 701 (97) |
| CVD risk factors | ||
| Smoking (%) | 160 (29) | 225 (31) |
| BMI, kg/m2 |
30.8±9.4 n=533 |
29.8 (8.0) n=707 |
| Hypertension (%) | 224 (41) | 255 (31) |
| Hyperlipidemia (%) | 161 (29) | 189 (26) |
| Diabetes (%) | 88 (16) | 94 (13) |
| LDL, mg/dL |
108±34 n=502 |
112±33 n=626 |
| RA‐related measures | ||
| ESR, mm/h |
24 (12–40) n=523 |
26 (14–43) n=676 |
| RF positive (%) |
302 (55) n=389 |
338 (47) n=574 |
| ACPA positive (%) |
177 (32) n=342 |
198 (28) n=569 |
| Medicationsa | ||
| NSAIDs (%) | 437 (80) | 538 (75) |
| Corticosteroids (%) | 468 (86) | 596 (83) |
| Methotrexate (%) | 339 (62) | 532 (74) |
| TNF‐α inhibitors (%) | 224 (41) | 268 (37) |
| Statins (%) | 214 (39) | 280 (39) |
ACPA indicates anti–cyclic citrullinated peptide antibody; BMI, body mass index; CVD, cardiovascular disease; ESR, erythrocyte sedimentation rate; LDL, low‐density lipoprotein; NSAIDs, nonsteroidal anti‐inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF‐α, tumor necrosis factor α.
Classification of hydroxychloroquine and all medication use as ever and never is for descriptive purposes only. All medication use was treated as time varying in the analysis. Demographics, CVD risk factors, and RA‐related variables were measured as the closest values at RA diagnosis. Values are the number (percentage), mean±SD, or median (25th–75th percentiles), unless indicated otherwise.